Pathos was founded to revolutionize precision medicine in cancer by harnessing the power of machine learning to transform drug development. Pathos aims to accelerate traditional oncology approaches based upon a comprehensive and integrated data-first strategy to discover and develop drugs for precise biological pathways. Pathos is currently pursuing co-development and in-licensing opportunities to build a portfolio of clinical stage oncology assets, applying its technology to find the right patients and indications, resulting in a highly improved probability of success and faster time to market.
The founding team built and scaled Tempus Labs, an AI-enabled diagnostics company that has built the world’s largest library of clinical and molecular data and an operating system to make sense of it. Through this experience, the founders have seen how precision medicine can transform lives, yet many patients remain who need better therapies. A new approach is needed to change the paradigm of drug development to rapidly serve these unmet needs, highlighting a unique opportunity for Pathos to pursue. We’re looking for other trailblazers who see the world differently and want to forge this new path with us.
Our team is distributed across the US with hubs in New York and Salt Lake. While we still operate with the agility of a startup, we are scaling to advance our platform.
About the role
In this role, the person will pioneer efforts in the field of precision oncology. With expertise in Cancer Biology, the successful candidate will be instrumental in expanding our patient-derived cancer organoid platform, a pivotal component of our data-centric approach to cancer therapeutics. By establishing and refining the organoid models, validating the biological relevance of tumor microenvironment (TME) in the system, and designing tests to study drugs of different mechanism of action (MOA), including drugs with intrinsic tumor cell mechanism and drugs targeting TME such as immune checkpoint inhibitors (ICIs), this role will bridge the gap between our computational predictions and real-world experimental validations. Working from our Salt Lake City facility, the role not only will drive research and innovation but also mentor and lead team members, ensuring that our methodologies are both cutting-edge and replicable. This position offers a unique opportunity to shape the future of oncology treatments, directly contributing to Pathos' mission of delivering transformative outcomes for patients worldwide.
This person will be working in Salt Lake City.
Key Responsibilities
- Establish and validate patient-derived cancer organoid models for indications of interest.
- Study the interaction between tumor cells and TME cells in cancer organoid models and demonstrate disease relevance.
- Develop and validate proteomic profiling of our cancer organoid platform.
- Interpret and summarize research findings, presenting them effectively at both internal and external meetings to support decision making for the development or in-licensing of oncology assets.
- Stay current with advancements in high content imaging technologies and cancer biology research.
- Publish groundbreaking studies in high-impact journals and deliver presentations in prestigious conferences to disseminate our research findings and establish our scientific reputation.
- Train and direct Research Associates in established techniques and in development of novel assays.
Who you are:
- PhD in Cancer Biology, Cancer Immunology, Molecular and Cellular Biology, or a related field.
- A minimum of 3 years post-doctoral or industry experience in the field of in vitro cancer models.
- Strong background in cancer organoid models or cancer immunology research is highly preferred.
- Excellent analytical, problem-solving, and organizational skills.
- Strong written and verbal communication skills.
- Ability to work independently and collaboratively in a fast-paced, interdisciplinary environment.
- Driven by data, innovation, and a desire to contribute to groundbreaking advancements in cancer therapy.
#J-18808-Ljbffr
